Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
ORGANIZATION
Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
As debates for the FY2024 drug pricing reform get into full swing, this occasional interview series aims to illuminate the views of members of the Central Social Insurance Medical Council (Chuikyo). Patient benefits should be the top priority for reform…
To read the full story
Related Article
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
- Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
- Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
- Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
ORGANIZATION
- Japan Needs New Pricing Scheme for Regenerative Medicine: Industry Group
July 31, 2025
- Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
- Takeda Alumni Link with Osaka Biz Lobby to Support Drug Discovery
July 28, 2025
- JPMA Urges Safeguards for Patient Access in Any Future Drug Tariff Talks
July 24, 2025
- JPMA Selected for Japan Program to Cut Carbon Emissions
July 23, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…